L
Lorenz Trümper
Researcher at University of Göttingen
Publications - 276
Citations - 22696
Lorenz Trümper is an academic researcher from University of Göttingen. The author has contributed to research in topics: Lymphoma & Diffuse large B-cell lymphoma. The author has an hindex of 53, co-authored 260 publications receiving 19534 citations. Previous affiliations of Lorenz Trümper include Deutsche Forschungsgemeinschaft & University of Cologne.
Papers
More filters
Journal ArticleDOI
STAT3 is essential for Hodgkin lymphoma cell proliferation and is a target of tyrphostin AG17 which confers sensitization for apoptosis.
Udo Holtick,Martina Vockerodt,Diana Pinkert,Nils Schoof,Benjamin Stürzenhofecker,N. Kussebi,K Lauber,S Wesselborg,D Löffler,F Horn,Lorenz Trümper,Dieter Kube +11 more
TL;DR: Findings support the concept that STAT3 signaling is important in the pathogenesis of cHL and tyrphostins are agents for developing new therapeutic strategies.
Journal ArticleDOI
Populational equilibrium through exosome-mediated Wnt signaling in tumor progression of diffuse large B-cell lymphoma
Raphael Koch,Martin Demant,Thiha Aung,Nina Diering,Anna Cicholas,Bjoern Chapuy,Dirk Wenzel,Marlen Lahmann,Annemarie Güntsch,Christina Kiecke,Sabrina Becker,Timo Hupfeld,Vivek Venkataramani,Marita Ziepert,Lennart Opitz,Wolfram Klapper,Lorenz Trümper,Gerald Wulf +17 more
TL;DR: It is shown that diffuse large B-cell lymphomas possess a self-organized infrastructure comprising side population (SP) and non-SP cells, where transitions between clonogenic states are modulated by exosome-mediated Wnt signaling.
Journal ArticleDOI
Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group.
Christina Nickenig,Martin Dreyling,Eva Hoster,Michael Pfreundschuh,Lorenz Trümper,Marcel Reiser,Hannes Wandt,Eva Lengfelder,Michael Unterhalt,Wolfgang Hiddemann +9 more
TL;DR: In patients with advanced‐stage follicular lymphoma and mantle cell lymphoma, conventional chemotherapy remains a noncurative approach, and no major improvement in overall survival has been achieved in recent decades.
Journal ArticleDOI
IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group
Michaela Feuring-Buske,Michael Kneba,Michael Unterhalt,Andreas Engert,Martin Gramatzki,E. Hiller,Lorenz Trümper,Wolfram Brugger,H Ostermann,J Atzpodien,Michael Hallek,E Aulitzky,Wolfgang Hiddemann +12 more
TL;DR: This study confirms the moderate treatment-related toxicity and the high antilymphoma activity of rituximab in patients with relapsed follicular lymphoma.
Journal ArticleDOI
Genomic and transcriptomic changes complement each other in the pathogenesis of sporadic Burkitt lymphoma
Cristina López,Kortine Kleinheinz,Sietse M. Aukema,Marius Rohde,Stephan H. Bernhart,Daniel Hübschmann,Rabea Wagener,Rabea Wagener,Umut H. Toprak,Umut H. Toprak,Francesco Raimondi,Markus Kreuz,Sebastian M. Waszak,Zhiqin Huang,Lina Sieverling,Nagarajan Paramasivam,Nagarajan Paramasivam,Julian Seufert,Stephanie Sungalee,Robert B. Russell,Julia Bausinger,Helene Kretzmer,Ole Ammerpohl,Anke K. Bergmann,Hans Binder,Arndt Borkhardt,Benedikt Brors,Alexander Claviez,Gero Doose,Lars Feuerbach,Andrea Haake,Martin-Leo Hansmann,Jessica I. Hoell,Michael Hummel,Jan O. Korbel,Chris Lawerenz,Dido Lenze,Bernhard Radlwimmer,Julia Richter,Philip Rosenstiel,Andreas Rosenwald,Markus Schilhabel,Harald Stein,Stephan Stilgenbauer,Peter F. Stadler,Monika Szczepanowski,Marc A. Weniger,Marc Zapatka,Roland Eils,Roland Eils,Peter Lichter,Markus Loeffler,Peter Möller,Lorenz Trümper,Wolfram Klapper,Steve Hoffmann,Ralf Küppers,Birgit Burkhardt,Matthias Schlesner,Reiner Siebert,Reiner Siebert +60 more
TL;DR: Interaction of structural, mutational, and transcriptional changes, which contribute to MYC oncogene dysregulation together with the pathognomonic IG-MYC translocation are unraveled.